A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide

A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide

Abstract Purpose To investigate whether palonosetron is better than granisetron in preventing chemotherapy‐induced nausea and vomiting (CINV) in a three‐drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC...

Full description

Bibliographic Details
Main Authors: Koji Matsumoto, Masato Takahashi, Kazuhiko Sato, Akihiko Osaki, Toshimi Takano, Yoichi Naito, Kazuo Matsuura, Kenjiro Aogi, Kimiko Fujiwara, Kenji Tamura, Motoi Baba, Shinya Tokunaga, Gen Hirano, Shigeru Imoto, Chieko Miyazaki, Kazuhiro Yanagihara, Chiyo K. Imamura, Yasutaka Chiba, Toshiaki Saeki
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Cancer Medicine
Subjects:
AC regimen
CINV
fosaprepitant
granisetron
palonosetron
Online Access:https://doi.org/10.1002/cam4.2979

Internet

https://doi.org/10.1002/cam4.2979

Similar Items